Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J H Porter

Showing results (211-220 of 298) with videos related to

Pageof 30
Sort By:
Molecular Pharmaceutics|May 21, 2009
Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimersLisa M Kaminskas, Brian D Kelly, Victoria M McLeod, et al.
Journal of Pharmaceutical Sciences|April 7, 2004
Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrineChristopher J H Porter, Ann Marie Kaukonen, Agnes Taillardat-Bertschinger, et al.
Pharmaceutical Research|March 12, 2010
The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623)Natalie L Trevaskis, Claire L McEvoy, Michelle P McIntosh, et al.
Molecular Pharmaceutics|April 24, 2015
Transformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulationsYasemin Sahbaz, Hywel D Williams, Tri-Hung Nguyen, et al.
Molecular Pharmaceutics|October 28, 2017
Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623Claire L McEvoy, Natalie L Trevaskis, Orlagh M Feeney, et al.
International Journal of Pharmaceutics|January 24, 2021
Intestinal delivery in a long-chain fatty acid formulation enables lymphatic transport and systemic exposure of orlistatGiven Lee, Sifei Han, Zijun Lu, et al.
Pharmacological Reviews|February 7, 2013
Strategies to address low drug solubility in discovery and developmentHywel D Williams, Natalie L Trevaskis, Susan A Charman, et al.
Biomacromolecules|July 22, 2017
An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous AdministrationLinda J Chan, Orlagh M Feeney, Nathania J Leong, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 19, 2013
PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastasesLisa M Kaminskas, David B Ascher, Victoria M McLeod, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 29, 2013
Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluationTri-Hung Nguyen, Angel Tan, Leilani Santos, et al.
Pageof 30

Showing results (211-220 of 298) with videos related to

Sort By:
Pageof 30
Molecular Pharmaceutics|May 21, 2009
Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimersLisa M Kaminskas, Brian D Kelly, Victoria M McLeod, et al.
Journal of Pharmaceutical Sciences|April 7, 2004
Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrineChristopher J H Porter, Ann Marie Kaukonen, Agnes Taillardat-Bertschinger, et al.
Pharmaceutical Research|March 12, 2010
The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623)Natalie L Trevaskis, Claire L McEvoy, Michelle P McIntosh, et al.
Molecular Pharmaceutics|April 24, 2015
Transformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulationsYasemin Sahbaz, Hywel D Williams, Tri-Hung Nguyen, et al.
Molecular Pharmaceutics|October 28, 2017
Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623Claire L McEvoy, Natalie L Trevaskis, Orlagh M Feeney, et al.
International Journal of Pharmaceutics|January 24, 2021
Intestinal delivery in a long-chain fatty acid formulation enables lymphatic transport and systemic exposure of orlistatGiven Lee, Sifei Han, Zijun Lu, et al.
Pharmacological Reviews|February 7, 2013
Strategies to address low drug solubility in discovery and developmentHywel D Williams, Natalie L Trevaskis, Susan A Charman, et al.
Biomacromolecules|July 22, 2017
An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous AdministrationLinda J Chan, Orlagh M Feeney, Nathania J Leong, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 19, 2013
PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastasesLisa M Kaminskas, David B Ascher, Victoria M McLeod, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 29, 2013
Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluationTri-Hung Nguyen, Angel Tan, Leilani Santos, et al.
Pageof 30